Download CV - Imperial College London

Justin Stebbing MA FRCP FRCPath PhD, 5-sided Curriculum vitae
PERSONAL DETAILS
Name
Date of birth
Nationality
NHS Work Address
Current Position
E mail
Justin STEBBING
21st January, 1971
British
Imperial College Healthcare NHS Trust, The Hammersmith Hospitals, Charing
Cross site, First Floor, East Wing, Fulham Palace Road, London, W6 8RF, UK
(w) 020 33118295(med sec); (f) 020 33461433; (private) 02073172573
Professor of Cancer Medicine and Medical Oncology, Imperial College. 2012
awarded The 1st NIHR Translational Research Professorship (by Dame Sally
Davies, the Chief Medical Officer).
[email protected] or [email protected]
Previously, senior lecturer in medical oncology at Imperial (2006 – 2010); specialist Registrar in Medical Oncology at Barts and the
London NHS Trust (2004 – 2006) and The Royal Marsden NHS Trust (1999 – 2001); Medical Research Council Clinical Training
Fellow, Imperial College London (2001 – 2003). Medical student at Trinity College Oxford (1989 – 1995) followed by a residency at The
Johns Hopkins Hospital, Baltimore, USA (1996 – 1999).
Editorial boards include Journal of Clinical Oncology, The Lancet Oncology and Oncogene, for which I am co-Editor-in-Chief. Other
positions include Chair of the Irish Cancer Society oversight committee, Board of Directors Curemark, Chair of Scientific Advisory
Boards Heat Biologics, Proton Partners, APIM Therapeutics, Imagen Biotech. In 2016 I was elected to be a Fellow of the American
Society for Clinical Investigation.
Founded Action Against Cancer, www.aacancer.org ; this has raised a substantial amount to support my research.
EDUCATION AND QUALIFICATIONS
2007
2006
2003
1998
1995
University 1989-1995:
1992
FRCPath
FACP
PhD
MRCP
BM BCh MA (Oxon.)
Oxford University School of Medicine, Trinity College.
Degree result: triple First class (BA in Physiological Sciences).
RECENT SELECTED PUBLICATIONS FROM 2012 - 2015 ONLY EMPHASISING BREADTH OF TUMOUR
TYPES AND COMBINATION OF CLINICAL CARE WITH RESEARCH:
2015:
1.
*Krell J*, Stebbing J*, Carissimi C, Dabrowska AF, de Giorgio A, Frampton A , Harding V, Fulci V, Macino G, Colombo T, Castellano L.
p53 regulates miRNA loading onto AGO2 and remodels the miRNA-mRNA interaction network. Genome Research, 2015, In press. *joint
first author.
2. Roca-Alonso L, Castellano L, Mills A, Dabrowska AF, Sikkel MD, Pellegrino L, Jacob J, Frampton AE, Krell J, Coombes RC, Harding SE,
Lyon AR, Stebbing J. Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in beta-adrenergic signalling and
enhances apoptosis. Cell Death and Disease, 2015;e1754.
3. Warusavitarne J, Stebbing J, Faiz O. Genetic variants and response to colon cancer treatment. Cancer, 2015;121:1735-1736.
4. Nacchiapan S, Askari A, Mamidanna R, Munasinghe A, Currie A, Stebbing J, Faiz O. The impact of chemotherapy timing on overall
survival following colorectal cancer resection. European Journal of Surgical Oncology, 2015;pii:S0478-7983.
5. Krell J, Gall T, Abbassi-Ghadi N, Mato Prado M, Giovannetti E, Castellano L, Habib N, Jiao L, Stebbing J. Prospective Validation of
microRNA Signatures for Detecting Pancreatic Malignant Transformation in Endoscopic-Ultrasound Guided Fine-Needle Aspiration
Biopsies. Oncotarget, 2015, In press.
6. Stebbing J, Zhang H, Xu Y, Grothey A, Ajuh P, Angelopoulos N, Giamas G. Reprogramming of the global tyrosine kinase-regulated
proteome by combined use of RNAi and SILAC-quantitative proteomics: the TK-Silacepedia. Molecular and Cellular Proteomics,
2015;14:2479-2492.
7. Xu Y, Zhang H, Nguyen V, Lit LC, Pedro J, Nunes FG, Reid A, Buluwela L, Magnani L, Stebbing J¥, Giamas G¥. Genome-wide mapping
identifies LMTK3 as an oncogenic transcriptional co-repressor with catalytic scaffold functions. Cell Reports, 2015;12:837-849. ¥Equal
contributors (joint last author).
8. Guttery DS, Page K, Hills A, Woodley L, Marchese SD, Rghebi B, Hastings RK, Luo J, Pringle JH, Stebbing J, Coombes RC, Ali S, Shaw
JA. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen-receptor positive metastatic breast cancer. Clinical
Chemistry, 2015;61:974-982.
9. Le Large TY, Frampton AE, Meijer LL, Stebbing J, Kazemier G, Giovannetti E. Usefulness of measuring microRNAs in bile and plasma
for pancreatic ductal adenocarcinoma diagnosis. American Journal of Gastroenterology, 2015;110:768-771.
10. Stebbing J, Zhang H, Xyu Y, Lit LC, Green AR, Grothey A, Lombardo Y, Periyasamy M, Blighe K, Zhang W, Shaw JA, Ellis IO, Lenz
1
Justin Stebbing MA FRCP FRCPath PhD, 5-sided Curriculum vitae
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
HJ, Giamas G. KSR1 regulated BRCA1 degradation and inhibits breast cancer growth. Oncogene, 2015;34:2103-2114.
Frampton AE, Stebbing J, Gall TM, Silver B, Jiao LR, Krell J. Activating mutations of GNAS and KRAS in cystic fluid can help detect
intraductal papillary mucinous neoplasms of the pancreas. Expert Reviews in Molecular Diagnostics, 2015;15:325-328.
Lombardo Y, de Giorgio A, Coombes CR, Stebbing J, Castellano L. Mammosphere formation assay from human breast cancer tissues and
cell lines. Journal of Visual Experimentation, 2015;10:e37951.
Merchant S, Stebbing J. Black cohosh, hot flushes and breast cancer. Lancet Oncology, 2015;16:137-138.
Warusavitarne J, Stebbing J. Probiotics and cancer: ready for meal time? Lancet Oncology, 2015;16:371-372.
Cathcart P, de Giorgio A, Stebbing J. Cannabis and cancer: reality or pipe dream. ? Lancet Oncology, 2015;16:1291-1292.
Pinato DJ, Stebbing J. Artemesia: a divine dart against cancer. Lancet Oncology, 2015;16:759-760.
Zhang H, Stebbing J, Giamas G. The many-faced KSR1: a tumor suppressor in breast cancer. Oncoscience, 2015;2:669-671.
Pinato DJ, Chowdhury S, Stebbing J. TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition. Oncogene,
2015, Epub ahead of print.
Mato Prado M, Frampton AE, Stebbing J, Krell J. Nanog: gene of the month. Journal of Clinical Pathology, 2015;68:763-755.
Frampton AE, Krell J, Jamieson NB, Gall TMH, Giovannetti E, Funel N, Prado MM, Krell D, Habib NA, Castellano L, Jiao LR, Stebbing
J. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: a meta-analysis. European Journal of Cancer,
2015;51:1389-1404.
Zhang H, Angelopoulos N, Xu Y, Grothey A, Nunes J, Stebbing J. Giamas G. Proteomic profiling of KSR1-regulated signalling in
response to genotoxic agents in breast cancer. Breast Cancer Research and Treatment, 2015;151:555-568.
Cathcart P, Lucchesi W, Ottaviani S, de Giorgio A, Krell J, Stebbing J, Castellano L. Noncoding RNAs and control of nuclear receptor
signalling in health and disease. Best Practice Research in Clinical Endocrinology and Metabolism, 2015;29:529-543.
Mapelli P, Aboagye EO, Stebbing J, Sharma R. Epigenetic changes in gastroenteropancreatic neuroendocrine tumours. Oncogene,
2015;34:4439-4447.
Schofield G, Urch CE, Stebbing J, Giamas G. When does a human being die? Quarterly Journal of Medicine, 2015;108:605-609.
Subsequent letter published too.
Sagoo MS, Filipovic A, Al Harby L, Stebbing J. Rare tumours: an eye on the future. Future Oncology, 2015, Epub ahead of print.
Oskrochi Y, Razi K, Stebbing J, Crane J. Angiosarcoma and dialysis-related arteriovenous fistulae: a systematic review. European Journal
of Vascular and Endovascular Surgery, 2015;pii:S1078-5884.
Rampias T, Favicchio R, Stebbing J, Giamas G. Targeting tumor-stroma cross-talk: the example of the NT157 inhibitor. Oncogene, 2015,
Epub ahead of print.
2014:
28. Krell J, Stebbing J. A stage-guided stratified approach for AIDS-related Kaposi’s sarcoma: broader implications. Journal of Clinical
Oncology, 2014;32:373-375.
29. Xu Y, Zhang H, Lit LC, Grothey A, Athanasiadou M, Kiritsi M, Lombardo Y, Frampton AE, Green AR, Ellis IO, Lenz HJ, Thanou M,
Giamas G, Stebbing J. LMTK3-GRB2 complex formation promotes tumor invasion by regulating transcription of integrin 1. Science
Signaling, 2014;7:ra58.
30. Stebbing J, Lit LC, Darrington S, Melaiu O, Giamas G. The regulatory roles of phosphatases in cancer. Oncogene, 2014;33:939-953.
31. Ottaviani S, de Giorgio A, Harding VF, Stebbing J, Castellano L. Non-coding RNAs and the control of hormonal signaling via nuclear
receptor regulation. Journal of Molecular Endocrinology, 2014;53:R61-R70.
32. Gall TM, Jacob J, Frampton AE, Krell J, Kyriakides C, Castellano L, Stebbing J, Jiao LR. Reduced dissemination of circulating tumor cells
with no-touch isolation surgical technique in patients with pancreatic cancer. JAMA Surgery, 2014;149:482-485.
33. Frampton AE, Krell J, Gall TM, Castellano L, Stebbing J, Jiao LR. miR-15b and miR-17 are tumor-derived plasma microRNAs
dysregulated in colorectal neoplasia. Annals of Surgery, 2014, Epub ahead of print.
34. Hardt A, Krell J, Wilson PD, Harding V, Chowdhury S, Mazhar D, Berney D, Stebbing J, Shamash J. Brain metastases associated with
germ cell tumors may be treated with chemotherapy alone. Cancer, 2014;120:1649-1646.
35. Pinato DJ, Karamanakos G, Arizumi T, Adjogatse D, Kim YW, Stebbing J, Kudo M, Jang JW, Sharma R. Dynamic changes of the
inflammation-based index predict mortality following chemoembolization for hepatocellular carcinoma: a prospective study. Alimentary
Pharmacology and Therapeutics, 2014;40:1270-1281.
36. Bower M, Stebbing J. Exploiting interleukin-6 in multicentric Castleman’s disease. The Lancet Oncology, 2014;15:910-912.
37. Froeling FE, Stebbing J. Uncaria tomentosa, the cat’s whiskers or claws. The Lancet Oncology, 2014;15:1299-1300.
38. Mapelli P, Aboagye EO, Stebbing J, Sharma R. Epigenetic changes in gastroenteropancreatic neuroendocrine tumours. Oncogene, 2014,
Epub ahead of print.
39. Pinato DJ, Shiner RJ, Seckl MJ, Stebbing J, Sharma R, Mauri FA. Prognostic performance of inflammation-based prognostic indices in
primary operable non-small cell lung cancer. British Journal of Cancer, 2014;110:1930-1935.
40. Shaw JA, Stebbing J. Circulating free DNA in the management of breast cancer. Annals of Translational Medicine, 2014;2:3-9.
41. Krell J, Frampton AE, Mirnezami R, Harding V, De Giorgio A, Roca Alonso L, Cohen P, Ottaviani S, Colomobo T, Jacob J, Pellegrino L,
Buchanan G, Stebbing J, Castellano L. Growth arrest-specific transcript 5 associated snoRNA levels are related to p53 expression and DNA
damage in colorectal cancer. PLoS One, 2014;9:e98561.
42. Britton D, Zen Y, Quaglia A, Selzer S, Mitra V, Löβner C, Jung S, Böhm G, Schmid P, Prefot O, Hoehle C, Koncarevic S, Gee J,
Nicholson R, Ward M, Stebbing J, et al. Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events
likely contributing to cancer and activity of drug targets. PLoS One, 2014;9:e90948.
43. Stebbing J, Paz K, Schwartz G, Wexler L, Maki R, Pollock R, Morris R, Cohen R, Shanker A, Blackman G, Harding V, Vasquez D, Katz
A, Krell J, Sidranksy D. Patient-derived xenografts for individualized care in advanced sarcoma. Cancer, 2014;120:2006-2015.
44. Blighe K, Kenny L, Patel N, Guttery DS, Page K, Gronau HJ, Golshani C, Stebbing J, Coombes RC, Shaw JA. Whole genome sequence
analysis suggests intratumoral heterogeneity in dissemination of breast cancer to lymph nodes. PLoS One, 2014;9:e115346.
45. Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, et al.
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet
2
Justin Stebbing MA FRCP FRCPath PhD, 5-sided Curriculum vitae
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
Oncology, 2014;15:406-414.
Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G,
Landi S. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural
mesothelioma. PLoS One, 2014,9:e85935.
Frampton AE¥, Castellano L¥, Colombo T, Giovannetti E, Krell J, Jacob J, Pellegrino L, Roca-Alonso L, Funel N, Fulci V, Britton BJ,
Ahmad R, Habib NA, Coombes RC, Knosel T, Stebbing J¥, Jiao LR¥. MicroRNAs acting in a co-operative manner induce pancreatic
¥
cancer progression through inhibition of a tumor suppressor gene network. Gastroenterology, 2014;146:268-277.
Equal
contributors.
Stebbing J, Harding V, Urch CE, Kaier T, Schofield G, Flook M, Alifrangis C, Young AM, Shaw Jam Coombes RC, Krell J. The
prognostic role of circulating tumour cells in heavily pre-treated individuals with a low life expectancy. Future Oncology, 2014;30:1-6.
Zhang H, Xu Y, Papanastasopoulos P, Stebbing J, Giamas G. Broader implications of SILAC-based proteomics for dissecting signaling
dynamics in cancer. Expert Review of Proteomics, 2014;11:713-731.
Harding V, Stebbing J. Crystals and cancer: good vibrations or bad intentions. The Lancet Oncology, 2014;15:263-265.
Januszewski A, Tanner N, Stebbing J. Ethnic variation in breast cancer incidence and otucomes – the debate continues. British Journal of
Cancer, 2014;110:4-6.
Mudan S, Giakoustidis A, Morrison D, Raobaikady R, Neofytou K, Stebbing J. 1000 Port-A-Cath placements by subclavian vein approach:
single surgeon experience. World Journal of Surgery, 2014;39:328-334.
Sagoo MS, Harbour JW, Stebbing J, Bowcock A. Combined PKC and MEK inhibition for treating metastatic uveal melanoma. Oncogene,
2014;33:4722-4723.
Frampton AE, Giovannetti E, Jamieson NB, Krell J, Gall TM, Stebbing J, Jiao LR, Castellano L. A microRNA meta-signature for
pancreatic ductal adenocarcinoma. Expert Reviews in Molecular Diagnostics, 2014;14:267-271.
Papanastasopoulos P, Stebbing J. Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer Research,
2014;34:1531-1535.
Winder T, Giamas G, Wilson PM, Zhang W, Yang D, Bohanes P, Ning Y, Gerger A, Stebbing J, Lenz HJ. Insulin-like growth factor
receptor polymorphisms defines clinical outcome in estrogen receptor positive breast cancer patients treated with tamoxifen.
Pharmacogenomics Journal, 2014;14:28-34.
Annels NE, Simpson GR, Denyer M, McGrath SE, Falgari G, Killick E, Eeles R, Stebbing J, Pchejetski D, Cutress R, Murray N, Pandha H.
Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer. Clinical and Experimental Immunology,
2014;177:428-438.
Januszewski A, Stebbing J. Hyperthermia and cancer – is it coming of age? Lancet Oncology, 2014;15:565-566.
Hills A, Stebbing J. Electrotherapy: enlightening modern medicine. Lancet Oncology, 2014;15:1060-1062.
Schofield G, Urch CE, Stebbing J, Giamas G. When does a human being die? Quarterly Journal of Medicine, 2014, Epub ahead of print.
Badreldin W, Krell J, Chowdhury S, Harland S, Mazhar D, Harding V, Frampton A, Wilson P, Berney D, Stebbing J, Shamash J. The
efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumors with high dose chemotherapy as consolidation – a noncisplatin based approach. British Journal of Urology International, 2014, Epub ahead of print.
Krell J, Stebbing J. Reply to stage stratified approach in Kaposi sarcoma. Journal of Clinical Oncology, 2014;32:1-2.
de Giorgio A, Castellano L, Krell J, Stebbing J. Crosstalk-induced loss of miR-126 promotes angiogenesis. Oncogene, 2014;33:3634-3636.
Benhaim L, Zhang W, Wakatsuki T, Yang D, Gerger P, Bohanes P, Paez P, Loupakis F, LaBonte MJ, Ning Y, El-Khoueiry R, Ladner R,
Wilson P, Zhang H, Giamas G, Stebbing J, Lenz HJ. Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients
with ERalpha-positive advanced breast cancer. The Pharmacogenomics Journal, 2014;15:235-240.
Alshaker H, Krell J, Frampton AE, Waxman J, Blyuss O, Zaikin A, Winkler M, Stebbing J, Yague E, Pchejetski D. Leptin induces
upregultion of sphingosine kinase-1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent
pathway. Breast Cancer Research and Treatment, 2014;16:426-436.
Alshaker H, Wang Q, Frampton AE, Krell J, Waxman J, Winkler M, Stebbing J, Cooper C, Yague E, Pchejetski D. Sphingosine kinase 1
contributes to leptin-induced STAT2 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer.
Breast Cancer Research and Treatment, 2014;149:59-67.
2013:
67. Stebbing J, Payne R, Reise J, Avery M, Woodley L, Di Leo A, Pestrin M, Krell J, Coombes RC. The efficacy of lapatinib in metastatic
breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells. PLoS One, 2013;8:e62543.
68. Gall TM, Frampton AE, Krell J, Jacob J, Stebbing J, Jiao LR. Is the detection of circulating tumor cells in locally advanced pancreatic
cancer a useful prognostic marker. Expert Reviews in Molecular Diagnostics, 2013;13:793-796.
69. Lee B, Lim AK, Krell J, Satchithanandra K, Coombes RC, Lewis JS, Stebbing J. The efficacy of axillary ultrasound in the detection of
nodal metastasis in breast cancer and its impact on clinical practice. American Journal of Radiology, 2013;200:W314-320.
70. Shaw J, Graham T, Stebbing J. Genomic instability in pre-neoplastic colonic lesions. Oncogene, 2013;32:5331-5334.
71. Castellano L, Stebbing J. Deep sequencing of small RNAs identifies canonical and noncanonical miRNA and endogenous siRNAs in
mammalian somatic tissues. Nucleic Acids Research, 2013;41:3339-3351.
72. Filipovic A, Stebbing J, Giamas G. Cancer stem cells – therapeutic targeting or therapy. Lancet Oncology, 2013;14:579-580.
73. De Giorgio A, Stebbing J. Misteltoe – for cancer or just for Christmas. Lancet Oncology, 2013;14:1264-1266.
74. Papanastasopoulos P, Stebbing J. Nuts and cancer: where are we now? Lancet Oncology, 2013;14:1161-1163.
75. Siegel AB, Stebbing J. Milk thistle: early seeds of potential for cancer prevention and treatment. Lancet Oncology, 2013;14:929-930.
76. Stebbing J, Gajapathy V, Lowdell C. Chocolate – delicious beauty or harmful beast? Lancet Oncology, 2013;14:557-460.
77. Stebbing J, Filipovic A, Giamas G. Claudin-1 as a promoter of EMT in hepatocellular carcinoma. Oncogene, 2013;14:579-580.
78. Lit LC, Scott S, Zhang H, Stebbing J, Photiou A, Giamas G. LATS2 is a modulator of estrogen receptor-alpha. Anticancer Research,
2013;33:53-63.
79. Frampton AE, Gall TM, Castellano L, Stebbing J, Jiao LR, Krell J. Towards a clinical use of miRNAs in pancreatic cancer biopsies. Expert
Reviews in Molecular Diagnostics, 2013;13:31-34.
3
Justin Stebbing MA FRCP FRCPath PhD, 5-sided Curriculum vitae
80. Pellegrino L*, Stebbing J*, Braga VM, Frampton AE, Jacob J, Buluwela L, Jiao LR, Periyasamy M, Madsen CD, Caley MP, Ottaviani S,
Roca-Alonso L, El-Bahrawy M, Coombes RC, Krell J, Castellano L. miR-23b regulates cytoskeletal remodeling, motility and metastasis by
directly targeting multiple transcripts. Nucleic Acids Research, 2013;41:5400-5412. *Joint first authors.
81. Payne SL, Krell J, Wilson P, Ansell W, Stebbing J, Shamash J. The efficacy and toxicity of tacrolimus and sirolimus in heavily pre-treated
unresectable thymic malignancies. Lung Cancer, 2013;80:228-239.
82. Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskoven S, Iqbal S, Danenberg DD, Kahn M, Teo JL, Shriki
J, Stebbing J, Lenz HZ. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in
patients with metastatic colorectal cancer (mCRC) treated with bevacizumab-based chemotherapy. Pharmacogenomics Journal,
2013;13:173-180.
83. Krell J, Frampton AE, Stebbing J. MicroRNAs in the cancer clinic. Frontiers Biosciences (Elite Ed), 2013;E5:204-213.
84. Krell D, Stebbing J. Aristolochia: the malignant truth. Lancet Oncology, 2013;14:25-26.
85. Wakatsuki T, LaBonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Brazi A, Ning Y, Loupakis F, Saadat S, Volz N, Stintzing S, ElKhoueiry R, Koizumi W, Watanabe M, Shah M, Stebbing J, Giamas G, Lenz HJ. Prognostic role of lemur tyrosine kinase-3 germline
polymorphisms on adjuvant gastric cancer in Japan and United States. Molecular Cancer Therapeutics, 2013;12:2261-2272.
86. Ramaswami R, Stebbing J. Ginseng: panacea among herbal remedies. Lancet Oncology, 2013;14:195-196.
87. Kitchen D, O’Brien M, Hughes B, Gill I, Rumbles S, Ellis P, Stebbing J. The efficacy and toxicity of gemcitabine, carboplatin and
bevacizumab in metastatic breast cancer. British Journal of Cancer, 2013;109:526-528.
88. Harding V, Stebbing J, Krell J. Bevacizumab in metastatic breast cancer. Clinical Oncology, 2013, In press.
89. Gall TM, Frampton AE, Krell J, Castellano L, Stebbing J, Jiao LR. Blood-based miRNAs as noninvasive diagnostic and surrogative
biomarkers in colorectal cancer. Expert Reviews in Molecular Diagnosis, 2013;13:141-145.
90. Page K, Guttery DS, Zahra N, Primrose L, Elshaw SR, Pringle JH, Blighe K, Marchese SD, Hills A, Woodley L, Stebbing J, Coombes RC,
Shaw JA. Influence of plasma processing on recovery and analysis of circulating nucleic acids. PLoS One, 2013;18:e77963.
91. Coombes RC, Tat T, Miller ML, Reise JA, Mansi JL, Hadjiminas DJ, Shousha S, Elsheikh SE, Lam EW, Horimoto Y, El-Bahrawy M,
Aboagye EO, Contractor KB, Shaw JA, Marconell MH, Palmieri C, Stebbing J. An open-label study of lapatinib in women with HER-2negative early breast cancer: the lapatinib pre-surgical study (LPS study), Annals of Oncology, 2013;24:924-930.
92. Zhang H, Koo CY, Stebbing J, Giamas G. The dual function of KSR1: a pseudokinase and beyond. Biochemical Society Transactions,
2013;41:1078-1082.
93. Zhang H, Xu Y, Filipovic A, Lit L, Koo C, Stebbing J, Giamas G. SILAC-based phospho-proteomics reveals an inhibitory role of KSR1 in
p53 transcriptional activity via modulation of DBC1. British Journal of Cancer, 2013;109:2675-2684.
94. Pinho FG, Frampton AE, Nunes J, Krell J, Alshaker HA, Jacob J, Pellegrino L, Roca-Alonso L, de Giorgio A, Harding V, Waxman J,
Stebbing J, Pchejetski D, Castellano L. Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase-1 and
breast cancer cell proliferation. Cancer Research, 2013;73:5936-5948.
95. Harding V, Afshar M, Krell J, Ramaswami R, Twelves CJ, Stebbing J. “Being there” for women with metastatic breast cancer: a panEuropean patient survey. British Journal of Cancer, 2013;109:1543-1548.
96. Krell J, Frampton AE, Colombo T, Gall TM, De Giorgio A, Harding V, Stebbing J, Castellano L. The p53 miRNA interactome and its
potential role in the cancer clinic. Epigenomics, 2013;5:417-428.
97. Pellegrino L, Krell J, Roca-Alonso L, Stebbing J, Castellano L. MicroRNA-23b regulates cellular architecture and impairs motogenic and
invasive phenotypes during cancer progression. Bioarchitecture, 2013;14:5-12.
98. Stebbing J, Filipovic A, Lit LC, Blighe K, Grothey A, Yasuhiro M, Chow LWC, Coombes RC, Sasano H, Shaw JA, Giamas G. LMTK3 is
implicated in endocrine resistance via multiple signaling pathways. Oncogene, 2013;32:3371-3380.
99. Ng T, Stebbing J. BRCA1 mutations and luminal-basal transformation. Oncogene, 2013;32:2712-2714.
100. Gall TM, Frampton AE, Krell J, Habib NA, Castellano L, Stebbing J, Jiao LR. Cell-free DNA for the detection of pancreatic, liver and
upper gastrointestinal cancers: has progress been made? Future Oncology, 2013;9:1861-1869.
101. Krell D, Mulholland P, Frampton AE, Krell J, Stebbing J, Bardella C. IDH mutations in tumorigenesis and their potential role as novel
therapeutic targets. Future Oncology, 2013;9:1923-1935.
102. Stebbing J. Cancer: Where were we, where are we, where are we going. Medical Legal Journal, 2014;9:3-8.
2012:
103. Krell J, Stebbing J. Circulating tumour cells as biomarkers in early breast cancer. Lancet Oncology, 2012;13:653-654.
104. Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, Kubota K, Sharma R. A novel and validated prognostic index in
hepatocellular carcinoma. Journal of Hepatology, 2012;57:1013-1020.
105. Alifrangis C, Stebbing J. Shark cartilage: has the popularisation of science failed. Lancet Oncology, 2012;13:22-23.
106. O’Cathail S, Stebbing J. Ayurvedic medicine: alternative or complementary? Lancet Oncology, 2012;13:865-866.
107. Krell J, Frampton AE, Jacob J, Castellano L, Stebbing J. MicroRNAs in breast cancer: ready for real time? Pharmacogenomics,
2012;13:709-719.
108. Ezra D, Krell J, Rose GE, Bailly M, Stebbing J, Castellano L. Transcriptome-level microarray expression profiling implicates IGF-1 and
Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy. Journal of Clinical Pathology, 2012;65:608-613.
109. Jiao LR, Frampton AE, Jacob J, Pellegrino L, Krell J, Giamas G, Tsim N, Vlaviano P, Cohen P, Ahmed R, Keller A, Habib NA, Stebbing J,
Castellano L. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One,
2012;7:e32068.
110. Pshezhetskiy D, Nunes GF, Naymark M, Lysann S, Muhammad A, Keun A, Sturge J, Stebbing J, Waxman J. Circulating sphingosine-1phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection. British Journal of Cancer,
2012;106:909-915.
111. Stebbing J, Bower M. Cell free DNA as a biomarker in the context of cancer, viruses and methylation. Journal of Infectious Diseases,
2012;205:1032-1035.
112. Frampton AE, Krell J, Pellegrino L, Roca-Alonso L, Jiao LR, Stebbing J, Castellano L, Jacob J. Integrated analysis of microRNA and
mRNA profiles enables target acquisition in human cancers. Expert Anticancer Reviews, 2012;12:323-330.
4
Justin Stebbing MA FRCP FRCPath PhD, 5-sided Curriculum vitae
113. Frampton AE, Gall TM, Giovannetti E, Stebbing J, Castellano L, Jiao LR, Krell J. Distinct miRNA profiles are associated with malignant
transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use. Expert Reviews in Molecular Diagnostics,
2013;13:325-329.
114. Jacob J, Frampton AE, Castellano L, Stebbing J, Krell J. Retinoblastoma protein determines aggressiveness in triple-negative breast cancer.
Expert Reviews Anticancer Therapy, 2012;12:581-584.
115. Keeler BD, Krell J, Acheson AG, Brookes MJ, Stebbing J, Frampton AE. Is there a role for intravenous iron therapy in patients undergoing
colorectal cancer resection? Expert Reviews Anticancer Therapy, 2012;12:1407-1412.
116. Zhang H, Photiou A, Arnhild G, Stebbing J, Giamas G. The role of pseudokinases in cancer. Cell Signaling, 2012;24:1173-1184.
117. Frampton AE, Stebbing J. Raising a glass of wine against cancer, or not? Lancet Oncology, 2012;13:669-670.
118. Contractor K, Aboagye EO, Jacob J, Challapalli A, Coombes RC, Stebbing J. Monitoring early response to taxane therapy in advanced
breast cancer with circulating tumor cells and [18F]-3’deoxy-3’fluorothymidine positron emission tomography: a pilot study. Biomarkers,
2012;6:231-234.
119. Contractor K, Challapalli A, Tomasi G, Rosso L, Wasan H, Stebbing J, Kenny L, Mangar S, Riddle P, Palmieri C, Al-Nahhas A, Sharma R,
Turkheimer F, Coombes RC, Aboagye E. Imaging of cellular proliferation in liver metastases by [18F]fluorothymidine positron emission
tomography: effect of therapy. Physics in Medicine and Biology, 2012;57:3419-3433.
120. Krell J, Stebbing J. Ginger: the root of cancer therapy? Lancet Oncology, 2012;13:235-236.
121. Krell J, Frampton AE, Jacob J, Pellegrino L, Roca-Alonso L, Zeloof D, Alifrangis C, Lewis J, Jiao LR, Stebbing J, Castellano L. The role
of miR-9 and miR-151-5p in breast cancer metastasis: a comparison of primary and metastatic tumour samples. Molecular Diagnosis and
Therapy, 2012;16:167-172.
122. Frampton AE, Krell J, Zhang Y, Stebbing J, Castellano L, Jiao LR. The role of miR-10b in metastatic pancreatic ductal adenocarcinoma.
Surgery, 2012;152:936-938.
123. Shamash J, Jacob J, Agrawal S, Powles T, Mutsvangwa K, Wilson T, Stebbing J. Whole blood stem cell re-infusion and escalated dose
melphalan in castration-resistant prostate cancer: a phase 1 study. Clinical Cancer Research, 2012;18:2352-2359.
124. Imber C, Stebbing J, Shankar A. Improving outcomes in cholangiocarcinomas. Journal of Gastrointestinal Oncology, 2012;4:178-180.
125. Roca-Alonso L, Pellegrino L, Castellano L, Stebbing J. Breast cancer treatment and adverse cardiac events: what are the molecular
mechanisms. Cardiology, 2012;122:253-259.
126. Shavadia J, Shah R, Yonga G, Patel R, Stebbing J, Nelson M. The influence of antiretroviral therapy on the QTc interval in an African
cohort. Clinical Infectious Diseases, 2012;54:448-451.
127. Payne RE, Hava NL, Page K, Blighe K, Ward B, Slade M, Brown J, Guttery DS, Zaidi SAA, Stebbing J, Jacob J, Yague E, Shaw JA,
Coombes RC. The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast
cancer dormancy. British Journal of Cancer, 2012;106:375-382.
128. Krell J, Stebbing J. Coffee: the science and art of moderation. Lancet Oncology, 2012;13:457-458.
129. Stebbing J, Ellis P. An overview of drug development for metastatic breast cancer. British Journal of Nursing, 2012;21:S18-22.
130. Krell J, Frampton AE, Stebbing J. The clinical significance of tumor infiltrating lymphocytes in breast cancer: does subtype matter. BMC
Cancer, 2012;12:135-136.
131. Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, Battelli N, Ravaioli A, Gianni L, Di Marsico R, Tondini C, Gori S, Coombes RC,
Stebbing J, Biganzoli L, Buyse M, Di Leo A. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent
lapatinib in patients with HER-2-negative breast cancer and HER-2-positive circulating tumor cells. A proof of concept study. Breast
Cancer Research and Treatment, 2012;134:283-289.
132. Kitchen D, Hughes B, Gill I, O’Brien M, Rumbles S, Ellis P, Harper P, Stebbing J, Rohatgi N. The relationship between vitamin D and
chemotherapy-induced toxicity: a pilot study. British Journal of Cancer, 2012;107:158-161.
133. Hart C, Cohen R, Norwood M, Stebbing J. The emerging harm of antioxidants in carcinogenesis. Future Oncology, 2012;8:535-548.
134. Frampton AE, Krell J, Jacob J, Stebbing J, Castellano L, Jiao LR. Loss of miR-126 is crucial to pancreatic cancer progression. Expert
Reviews Anticancancer Therapy, 2012;12:881-884.
135. Krell J, Frampton AE, Jiao LR, Stebbing J. Can pharmacogenomics guide effective Anticancer therapy in pancreatic ductal
adenocarcinoma? Pharmacogenomics, 2012;13:977-999.
136. Stebbing J, Sharma A, North B, Athersuch TJ, Zebrowski A, Pchejetski D, Coombes RC, Nicholson JK, Keun HC. A metabolic
phenotyping approach to understanding relationships between metabolic syndrome and breast tumor responses to chemotherapy. Annals of
Oncology, 2012;23:860-866.
137. Shaw JA, Page K, Blighe K, Hava N, Guttery D, Ward B, Brown J, Ruangratheep C, Stebbing J, Payne R, Palmieri C, Cleator S, Walker
RA, Coombes RC. Genome analysis of circulating cell free DNA infers breast cancer dormancy. Genome Research, 2012;22:220-231.
138. Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D, Monteverde M, Merlano M, Papoudou-Bai A,
Schmid P, Stebbing J, Bower M, Dyer MJ, Karran LE, Farrell PJ, Thompson A, Briasoulis E, Crook T. The collagen prolyl hydroxylases
are novel transcriptionally silenced genes in lymphoma. British Journal of Cancer, 2012;107:1423-1432.
139. Guttery DS, Blighe K, Page K, Marchese SD, Hills A, Coombes RC, Stebbing J, Shaw JA. Hide and seek: tell-tale signs of cancer lurking
in the blood. Cancer Metastasis Reviews, 2012;32:289-302.
140. Frampton AE, Krell J, Giovannetti E, Krell D, Stebbing J, Castellano L, Jiao LR. Defining a prognostic molecular profile for ductal
adenocarcinoma of the pancreas highlights known key signalling pathways. Expert Reviews Anticancer Therapy, 2012;12:1275-1278.
141. Frampton AE, Krell J, Giovannetti E, Jiao LR, Stebbing J. Role of miRNAs in the response to Anticancer therapy. Pharmacogenomics,
2012;13:1663-1666.
142. Stebbing J, Filipovic A, Ellis IO, Green AR, Rapoz D-Silva T, Lenz HJ, Coombes RC, Wang T, Lee S-C, Giamas G. LMTK3 expression in
breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Research and Treatment, 2012;132:537-544.
References upon request (Professors Waxman and Lalvani: [email protected] and [email protected]).
5